Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
about
Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion modelAbsorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes.Improving In Vivo Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems.Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs.Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities.Evaluation of the Oral Bioavailability of Low Molecular Weight Heparin Formulated With Glycyrrhetinic Acid as Permeation EnhancerZonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin.Safety concerns over the use of intestinal permeation enhancers: A mini-reviewDelivery of optical contrast agents using Triton-X100, part 2: enhanced mucosal permeation for the detection of cancer biomarkers.Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.Basics and recent advances in peptide and protein drug delivery.Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.A prospective analysis of co-processed non-ionic surfactants in enhancing permeability of a model hydrophilic drug.In vitro assessment of alkylglycosides as permeability enhancers.Efficacious intestinal permeation enhancement induced by the sodium salt of 10-undecylenic acid, a medium chain fatty acid derivative.Enhanced Permeability of Etoposide across Everted Sacs of Rat Small Intestine by Vitamin E-TPGS.The influence of surfactant HLB and oil/surfactant ratio on the formation and properties of self-emulsifying pellets and microemulsion reconstitutionDesign of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability.Permeabilization of enterocytes induced by absorption of dietary fat.Assessment of methylsulfonylmethane as a permeability enhancer for regional EDTA chelation therapy.Self-emulsifying preconcentrates of daidzein-phospholipid complex: design, in vitro and in vivo appraisal.A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability.The utility of rat jejunal permeability for biopharmaceutics classification system.Development and evaluation of nanoemulsifying preconcentrate of curcumin for colon delivery.Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery.Prerequisite Characteristics of Nanocarriers Favoring Oral Insulin Delivery: Nanogels as an OpportunityMicroparticulate polyelectrolyte complexes for gentamicin transport across intestinal epitheliaEffect of bile on the oral absorption of halofantrine in polyethylene glycol 400 and polysorbate 80 formulations dosed to bile duct cannulated rats
P2860
Q28366175-E9DDA6A6-8A09-44B5-BD55-8DF2AAB5629CQ32062427-A15A673D-6088-434F-A291-ACEA5F4174A9Q33710442-E2CB5F37-36C3-459D-BB8E-983C444A3DFAQ34470793-F2246526-E47D-467A-90E3-89481723D263Q34532529-80024A77-DB97-4CD9-ADE4-249CE076BC44Q35941004-DA7CA78F-9D95-4524-AEA4-D9D0669D4F50Q36015126-8A1CAFD9-2C9A-4599-AA05-922F4648F49BQ37012940-F7FCCFCC-7EEB-4180-BB40-E826CD8FAE72Q37353336-B281F4BE-EE40-451A-9B6B-E2DBC40FBED4Q38115195-1E8A14A4-9DD0-4916-894A-EC9638255241Q38162494-DF093B7A-1B22-4DF3-ABB6-5BD8D821361AQ38181489-E89228D1-6E0F-47E9-9EF6-4F3BEAADF476Q38554851-9E4BB1B3-9372-402A-82AD-1383D4A15B3DQ40598740-C18E7A81-E70F-4D52-8B15-BD884DD5063BQ41782512-8646F4F0-9231-4B5F-BBE3-348361BE67D8Q41889524-ED347990-8C2A-487B-80A3-9A200871B382Q41988167-762DD7D2-AB03-4319-8F97-F779690F3868Q42012983-DF646F1E-ECEB-47F1-92B7-B711424C76A8Q42436222-7B60A492-DA2D-4AD1-B735-BC065EED0A91Q45963454-F8CE9706-0F2A-4C4A-A3F0-ED9BE5E832A8Q46420485-8E21708E-6EFD-4AFA-A649-64C5482CC516Q51255753-86976247-FE1D-4F61-922E-B19D25C87503Q51774073-BE7F58D0-281C-49E6-80DC-2C4F8A94D6E1Q53547627-A1EB0B21-A7F9-4A85-B49A-D9E57C695CB5Q55223335-31A19EFE-128E-477C-AF63-CA1A79D189CFQ57348419-1F5C9AA9-29D6-4681-AB1D-0C95CD6D4204Q57382794-66E988D0-926D-4714-9B94-B71A9BA37FD6Q58199089-38306685-D9B5-4F03-B678-43DE41D3EF57
P2860
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
description
1994 nî lūn-bûn
@nan
1994 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@ast
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@en
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@nl
type
label
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@ast
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@en
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@nl
prefLabel
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@ast
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@en
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@nl
P2093
P356
P1476
Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
@en
P2093
Curatolo W
Milisen WB
Swenson ES
P304
P356
10.1023/A:1018984731584
P577
1994-08-01T00:00:00Z